Exosomes and Carcinogenesis
Tumor-derived exosomes are implicated in carcinogenesis through intercellular transfer of oncogenic proteins, lipids, and nucleic acids that promote malignant progression. Exosomes also support key tumor hallmarks such as immune evasion, tumor microenvironment remodeling, angiogenesis, metastatic dissemination, and chemotherapy resistance. [1]
Biological Basis for a Carcinogenic Relationship
Exosomes are nanoscale extracellular vesicles secreted via endosomal pathways that mediate intercellular communication. [1] Exosomal cargo can functionally reprogram recipient cells by delivering bioactive molecules, enabling pro-tumor phenotypes to spread within the tumor microenvironment. [1]
Mechanisms Linking Exosomes to Malignant Progression
Exosomes participate in metastatic dissemination by promoting communication between tumor cells and permissive niche cells. [1] Exosomes contribute to immune evasion through modulation of anti-tumor immune responses. [1] Exosomes remodel the tumor microenvironment by altering the behavior of stromal and immune compartments. [1] Exosomes can promote angiogenesis via signaling that supports neovascularization. [1] Exosomes can contribute to chemoresistance through transfer of factors that reduce treatment sensitivity. [1]
Secretion Pathways as Targets of Tumor Biology
Rab27 is a molecular regulator of tumor exosome secretion. [2] Rab27 promotes malignant progression by modulating exosome secretion. [2] Aberrant Rab27 expression is associated with cancer prognosis and is proposed as a prognostic biomarker across malignancies. [2] Targeting the exosome secretory pathway via Rab27 inhibition is described as a strategy with antitumor potential. [2]
Exosomes as Biomarkers of Cancer Biology
Tumor-derived exosomes are investigated as diagnostic biomarkers, including in liquid biopsy contexts. [1] Exosome surface epitopes and molecular profiling are used to trace vesicle origin and enable enrichment of tissue-specific molecular signatures. [1]
Exosome-Related Genomic Signatures and Prognosis
Exosome-related mRNA signatures have been reported to correlate with prognosis and the immune microenvironment in breast cancer. [3] In that reported work, exosome-related mRNAs were used to construct a prognostic risk model and stratify patients by overall survival with parallel associations to tumor microenvironment features. [3]
Limitations and Interpretation Considerations
Most evidence for exosome roles in carcinogenesis is mechanistic and translational, with strong laboratory support for biologic plausibility. [1] Clinical utility is still constrained by issues in exosome isolation, vesicle heterogeneity, and standardization of exosome characterization and attribution to tumor origin. [1]
Therapeutic Targeting Concepts
Exosome biogenesis and release pathways are described as therapeutic targets in oncology, including pharmacologic or genetic strategies directed at exosome production and secretion. [1] Interference with exosome secretory machinery is positioned as a way to reduce pro-tumor signaling mediated by tumor-derived vesicles. [2] Engineered exosomes and vesicle-based platforms are discussed as delivery approaches that exploit exosomal cargo-loading and biocompatibility. [1]
Bottom-Stage Clinical Implication
An established relationship exists between exosomes and carcinogenesis through tumor-mediated vesicle signaling that drives malignant progression and therapy resistance. [1] This relationship supports ongoing development of exosome-based biomarkers and interventions targeting exosome biogenesis, secretion, or vesicle-mediated communication. [1][2]